סך נכסי הפעילות העסקית Ensysce (ENSC)

Ensysce Biosciences (ENSC) relies on a team of leading toxicologists to develop an abuse-deterrent system. However, the business depends on the FDA verdict regarding MPAR and requires equity offerings to fund testing. This chart on GURU.Markets reflects a price trend with total assets at 4.26. Growth potential remains high due to proprietary formulas that enable the scaling of analgesic sales globally.

The unique TAAP platform provides Ensysce Biosciences (ENSC) with significant pricing power by protecting drugs from abuse, while the value of the company's financial assets reflects the market value of capital and liabilities, calculated reversely through the daily return on assets (ROA). This indicator's trend allows investors to identify hidden balance sheet distortions and assess the real efficiency of resource utilization within the context of the issuer's technological superiority.